Document is current
Any future updates will be listed below
-
Authors
Silverberg, Jonathan I. https://orcid.org/0000-0003-3686-7805
Agner, Tove https://orcid.org/0000-0002-7543-8299
Baranowski, Keith https://orcid.org/0009-0007-2333-0896
Plohberger, Ursula https://orcid.org/0009-0005-7351-8825
Thoning, Henrik
Arbuckle, Rob https://orcid.org/0000-0003-0345-2523
Grant, Laura
Skingley, George https://orcid.org/0000-0002-7115-0394
Bissonnette, Robert https://orcid.org/0000-0001-5927-6587
-
Funding
Funding for this research was provided by:
Leo Pharma
- License Information
-
More Information
Article History
Received: 20 December 2023
Revised: 20 December 2023
Accepted: 11 January 2024
First Online: 20 March 2024
Declarations
:
: JS: has received honoraria as a consultant and/or advisory board member and/or speaker and/or received grants from AbbVie, Alamar, Aldena, Aobiome, Arcutis, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Bristell-Myers Sqibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, LEO Pharma A/S, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union.. TA: has given lectures, participated in clinical studies, or been on advisory boards for Sanofi, LEO Pharma, Pfizer, Eli Lilly, Galderma, and AbbVie. KB, UP, HT: are employees of LEO Pharma A/S, Ballerup, Denmark. RA, LG, GS: are employees of Adelphi Values, Patient-Centered Outcomes, Cheshire UK, and Adelphi Values was contracted by LEO Pharma to support them in performing the psychometric analyses. RB: is an advisory board member, consultant, speaker and/or investigator for and receives honoraria and/or grants from AbbVie, Arcutis, Arena Pharma, Asana BioSciences, Bellus Health, Boehringer-Ingelheim, CARA, Dermavant, Eli Lilly, EMD Serono, Galderma, Incyte, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Pfizer, Ralexar, RAPT, Regeneron, Sanofi Genzyme, and Sienna. He is also an employee and shareholder of Innovaderm Research.
: The trial was conducted in accordance with the consensus of ethical principles from internal guidelines including the Declaration of Helsinki, Council for Internal Organization of Medical Sciences (CIOMS) International Ethical Guidelines, International Council of Harmonization Good Clinical Practice (ICH GCP) Guideline, EU General Data Regulation 2016/679 of 27 April 2016 and in compliance with the approved protocol and applicable laws and regulations. All procedures involving study participants were approved by the institutional review board or independent ethics committees at all investigational sites.
: Written informed consent to participate in the trial and publication was obtained from all subjects.
